The evaluation of neuroprotective efficacy of newly developed oximes (K074, K075) and currently available oximes (obidoxime, HI-6) in cyclosarin-poisoned rats.
The neuroprotective effects of newly developed oximes (K074, K075) and currently available oximes (obidoxime, HI-6) in combination with atropine in rats poisoned with cyclosarin were studied. The cyclosarin-induced neurotoxicity was monitored using a functional observational battery at 24 h and 7 days following cyclosarin challenge. The results indicate that the oxime HI-6 combined with atropine seems to be the most effective antidote for a decrease in cyclosarin-induced neurotoxicity. Both newly developed oximes (K074, K075) as well as obidoxime are also able to counteract cyclosarin-induced acute neurotoxicity, but their neuroprotective potency is significantly lower compared with the oxime HI-6. Therefore, the oxime HI-6 is still the most suitable oxime for the antidotal treatment of acute poisonings with cyclosarin due to its neuroprotective as well as reactivating efficacy.
Kassa
Jiri
J
Department of Toxicology, Faculty of Military Health Sciences, Hradec Kralove, Czech Republic. kassa@pmfhk.cz
Karasova
Jana
J
Vasina
Libor
L
D000110:Acetylcholinesterase / Q000378:metabolism; D000818:Animals; D000931:Antidotes / Q000494:pharmacology* / Q000627:therapeutic use; D001285:Atropine / Q000494:pharmacology* / Q000627:therapeutic use; D001341:Autonomic Nervous System / Q000187:drug effects; D002073:Butanes / Q000494:pharmacology; D002801:Cholinesterase Reactivators / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D020258:Neurotoxicity Syndromes / Q000201:enzymology / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D009768:Obidoxime Chloride / Q000494:pharmacology; D062025:Organophosphate Poisoning; D009943:Organophosphorus Compounds; D010091:Oximes / Q000494:pharmacology* / Q000627:therapeutic use; D011726:Pyridinium Compounds / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012677:Sensation / Q000187:drug effects; D013997:Time Factors
C515196:1,4-bis(4-hydroxyiminomethylpyridinium)butane dibromide; D000931:Antidotes; D002073:Butanes; D002801:Cholinesterase Reactivators; C518856:K075 compound; D018696:Neuroprotective Agents; D009943:Organophosphorus Compounds; D010091:Oximes; D011726:Pyridinium Compounds; D009768:Obidoxime Chloride; D001285:Atropine; D000110:Acetylcholinesterase; C022870:asoxime chloride; C053914:cyclohexyl methylphosphonofluoridate